Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 27(7): 1611-1615, 2017 04 01.
Article in English | MEDLINE | ID: mdl-28238612

ABSTRACT

Novel cytotoxins 3-5 containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore are disclosed. The compounds in series 3 and 5 have the potential to liberate niacin which may reduce some of the side effects of antineoplastic compounds. 3a-c emerged as the most potent cytotoxic compounds with IC50 values in the low micromolar range against human Molt4/C8 and CEM CD4+ T-lymphocytes as well as murine L1210 leukemia cells. QSAR studies revealed that cytotoxic potencies were negatively correlated with the magnitude of the Hammett sigma values of the aryl substituents. The compounds 3a-e displayed tumour-selective toxicity against human HL-60, HSC-2, HSC-3 and HSC-4 neoplasms as compared to human HGF, HPC and HPLF nonmalignant cells. A representative potent compound 3a caused PARP1 cleavage and G0/G1 cell cycle arrest in HSC-2 cells. These compounds are well tolerated in mice at doses up to and including 300mg/kg of the compounds and no mortalities were noted after 4h. The stability studies undertaken did not reveal that a representative compound 3a underwent hydrolysis to the related phenol 2a. Some guidelines for further analog development of the novel esters 3 were made.


Subject(s)
Antineoplastic Agents/pharmacology , Benzylidene Compounds/pharmacology , Cyclohexanones/pharmacology , Niacin/analogs & derivatives , Niacin/pharmacology , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/toxicity , Benzylidene Compounds/administration & dosage , Benzylidene Compounds/chemical synthesis , Benzylidene Compounds/toxicity , Cell Line, Tumor , Cyclohexanones/administration & dosage , Cyclohexanones/chemical synthesis , Cyclohexanones/toxicity , Drug Screening Assays, Antitumor , G1 Phase Cell Cycle Checkpoints/drug effects , Humans , Hydrolysis , Melphalan/pharmacology , Mice , Niacin/administration & dosage , Niacin/chemical synthesis , Niacin/toxicity , Poly (ADP-Ribose) Polymerase-1/chemistry , Quantitative Structure-Activity Relationship , Rats
2.
J Enzyme Inhib Med Chem ; 31(6): 1451-6, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27251045

ABSTRACT

Novel series of niacin esters of chalcones 2, 4 and 6 were designed as antineoplastic agents that have the potential to release the chemoprotectant niacin. These enones are cytotoxic to human CD4(+ )T-lymphocyte Molt 4/C8 and CEM and murine leukemia L1210 cells. Quantitative structure-activity relationship (QSAR) studies of the biodata in series 4 revealed that cytotoxic potency was enhanced by placing electron-repelling groups in one of the aryl rings. The compounds are lethal to HL-60, HSC-2, HSC-3 and HSC-4 neoplasms but less toxic to nonmalignant hepatocyte growth factor, hematopoietic progenitor cell and human periodontal ligament fibroblast cells. Hence, the compounds display tumor-selective toxicity. These chalcones are well tolerated in mice and no overt toxicity was noted. The results establish that in general the compounds in series 2, 4 and 6 have positive characteristics which warrant further studies.


Subject(s)
Antineoplastic Agents/pharmacology , Chalcones/chemistry , Chalcones/pharmacology , Niacin/chemistry , Carbon-13 Magnetic Resonance Spectroscopy , Cell Line, Tumor , Drug Screening Assays, Antitumor , Esters , Humans , Proton Magnetic Resonance Spectroscopy
3.
Bioorg Med Chem ; 17(11): 3909-15, 2009 Jun 01.
Article in English | MEDLINE | ID: mdl-19427790

ABSTRACT

A series of 2-(3-aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides 3a-l were prepared by condensation of various aryl aldehydes with 2-acetyl-3-methylquinoxaline-1,4-dioxide 2. These compounds inhibit the growth of human Molt 4/C8 and CEM T-lymphocytes and the IC(50) values are mainly in the 5-30 microM range. The quinoxaline 1,4-dioxide 3j inhibited the growth of 58 human tumor cell lines, particularly leukemic and breast cancer neoplasms. All of the compounds 3a-l reversed the multidrug resistance (MDR) properties of murine L-5178Y leukemic cells which were transfected with the human MDR1 gene. The MDR-reversing effect may be due to the conjugated pi-electron system forming a weak electron charge transfer complex with the P-glycoprotein-mediated efflux pump. The compounds in series 2 and 3 were assessed against HL-60, HSC-2, HSC-3 and HSC-4 malignant cells as well as HGF, HPC and HPLF normal cell lines which revealed that the majority of the compounds displayed a greater toxicity to neoplastic than normal cells. Various ways in which the project may be expanded are presented.


Subject(s)
Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Oxides/chemistry , Oxides/pharmacology , Quinoxalines/chemistry , Quinoxalines/pharmacology , Animals , Cell Line, Tumor , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Drug Screening Assays, Antitumor , Female , Humans , Inhibitory Concentration 50 , Male , Mice , Molecular Structure , Neoplasms/drug therapy , Oxides/chemical synthesis , Quantitative Structure-Activity Relationship , Quinoxalines/chemical synthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...